As part of our continuing coverage from the BIO International Convention 2026, Pharmaceutical Executive spoke with Martha Fowler, founder of Steer Bio, about the company's regenerative medicine platform, its lead program for cancer-related lymphedema, and how non-dilutive funding is supporting its path toward first-in-human studies.
At the BIO International Convention 2026 in San Diego, CA, last month, Pharmaceutical Executive caught up with Christy Wyskiel, executive director of Johns Hopkins Technology Ventures, to discuss how the institution is translating research into commercial products, supporting startup creation, and strengthening Baltimore's life sciences innovation community through strategic partnerships.
Abu Dhabi is expanding its role in global biopharmaceutical manufacturing through strategic investments, advanced infrastructure, and international partnerships designed to accelerate biologics production, innovation, and supply chain resilience.
Jeff Talbot of Roseman University of Health Sciences discusses how Las Vegas is positioning itself as a growing life sciences hub by offering cost-effective laboratory space, access to capital, and a flexible environment for biotech startups and emerging companies.
Advancements in periodontal disease could make way for expansions in the dental space and other medical fields.
Hugues Wallemacq, CEO of EXO Biologics, discusses the company's innovative approach to developing scalable and GMP-compliant exosome therapies and ambitious plans to reshape the global therapeutic landscapes.
Shawn Davis, CEO of Liberate Bio, shares some insights into the world of drug discovery, development, and delivery, as well as process optimization
Gabi Hanna, MD, CEO and Co-Founder of Lamassu Pharma talks about a novel oncology platform and the link between science and patient care.
Aliada Therapeutics' chief scientific officer, John Dunlop, PhD, discusses the novel platform.
